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Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to their underlying liver disease.
This study assessed the incidence of hepatotoxicity in HIV/HCV co-infected patients in two outpatient infectious diseases clinics.
Methods. HIV/HCV co-infected adults were included in this retrospective study if they were PI or NNRTI na¨ ıve at their ﬁrst
clinic visit and were initiated on an NNRTI- and/or PI-based antiretroviral regimen. Patients were excluded if they had active or
chronic hepatitis B virus (HBV). The primary objective was to determine the overall incidence of severe hepatotoxicity. Results.
Fifty-six of the 544 patients identiﬁed met inclusion criteria. The incidence of severe hepatotoxicity was 10.7% (6/56 patients).
Severe hepatotoxicity occurred with efavirenz (N = 2), nevirapine (N = 1), indinavir (N = 1), nelﬁnavir (N = 1), and
saquinavir/ritonavir (N = 1). Conclusion. The incidence of severe hepatotoxicity appears to be low in this retrospective analysis of
HIV/HCV co-infected patients receiving a PI-and/or NNRTI-based regimen.
1.Introduction
The advent of highly active antiretroviral therapy (HAART)
in the treatment of human immunodeﬁciency virus (HIV)
infection has signiﬁcantly decreased the incidence of oppor-
tunisticinfectionsaswellasimprovedmorbidityandmortal-
ity among HIV patients. However, along with these positive
outcomes, HAART is associated with a host of adverse reac-
tions such as hepatotoxicity, hyperlipidemia, hyperglycemia,
andlacticacidosis.HepatotoxicitycaninterruptHIVtherapy
and cause an increase in morbidity and mortality [1].
Protease Inhibitors (PIs), nonnucleoside reverse transcrip-
tase inhibitors (NNRTIs), and the chemokine receptor 5
(CCR5) antagonist, maraviroc, can be hepatotoxic with
asymptomatic elevations in transaminase levels and, rarely,
liverfailureanddeath[2].Approximately1/3ofHIVinfected
patients in the United States are coinfected with HIV and
hepatitis C (HCV) [3]. Often these patients have elevated
liver function tests secondary to chronic HCV infection,
which can be aggravated with the addition of hepatotoxic
antiretrovirals for the treatment of their HIV infection.
Several studies have evaluated hepatotoxicity associated
with HAART in patients coinfected with HIV and either
HCV or hepatitis B virus (HBV) [2–9]. HIV/HCV-co-
infection has been estimated to increase the risk of HAART-
associated hepatotoxicity 2- to 10-fold compared to HIV-
monoinfection [4, 5]. Published retrospective studies eval-
uating the risk of developing severe hepatotoxicity with
HAART in HIV/HCV-co-infected patients are limited by
their short followup time of approximately one year. In
addition, studies investigating exposure with newer protease
inhibitors have not beenperformed.This study evaluatedthe
eﬀect of HAART and hepatotoxicity in HIV/HCV coinfected
patients beginning with their initial visit at the Duke
University Medical Center (DUMC) Infectious Diseases
Clinic and the Durham Veterans Aﬀairs Medical Center
(DVAMC) Infectious Diseases Clinic between August 1, 1994
and December 31, 2006.2 AIDS Research and Treatment
2. Methods
This was a retrospective study conducted at the DUMC
and DVAMC Infectious Diseases Clinics and was approved
by the Institutional Review Boards of both facilities with a
waiver for patient consent. Medical and pharmacy records of
patients were reviewed to identify eligible patients. Patients
were included in the study if they met all of the following cri-
teria: ≥18 years of age, HIV-infected with HCV coinfection,
followed at either the DUMC or DVAMC Infectious Diseases
Clinics from their initial visit between August 1, 1994 and
December 31, 2006, PI or NNRTI na¨ ıve at their ﬁrst clinic
visit, received a PI- and/or NNRTI-based regimen during the
study period, and had baseline liver function tests (LFTs)
bothpriortostartingHAARTandduringtreatment.Patients
were excluded if they had active or chronic HBV.
The following data was collected: demographic infor-
mation, baseline liver enzymes (AST, ALT) prior to ﬁrst
antiretroviral therapy (ART) regimen and for subsequent
regimens that the patient was changed to, subsequent liver
enzymes during ART therapy for the study period, HCV
genotype, baseline and subsequent PI/NNRTI regimens
through December 31, 2006 and the duration of each regi-
men in months, data regarding rationale for changing PI or
NNRTI regimens, plasma HIV-RNA level at baseline deﬁned
as viral load closest in time to the ﬁrst HAART regimen,
CD4 lymphocyte count at baseline deﬁned as CD4 count
closest in time to the ﬁrst HAART regimen, HCV treatment
at any time, alcohol consumption at baseline deﬁned as no
intake, moderate intake (not >1 drink/day), heavy intake (>1
drink/day), or unable to determine, and subsequent alcohol
consumption was evaluated if LFT elevations were noted.
The primary endpoint of the study was to determine
the incidence of severe hepatotoxicity (deﬁned in accordance
with AIDS Clinical Trials Group criteria as grades 3 or
4) in coinfected HIV/HCV patients receiving a PI- and/or
NNRTI-based antiretroviral regimen [10]. In patients with
normalbaselinetransaminases,grades3and4hepatotoxicity
was deﬁned as an alanine aminotransferase (ALT) and/or
aspartate transaminase (AST) increase of 5.1−10 times the
upper limits of normal (ULN) or >10 times the ULN,
respectively. In patients with elevated baseline transaminases
grades 3 and 4 hepatotoxicity was deﬁned as an ALT
and/or AST increased to 3.6−5 times the patient’s baseline
values or >5 times the patient’s baseline, respectively. The
incidence was expressed as the number of episodes of severe
hepatotoxicity per person exposed during the study period.
Secondary endpoints were to determine the incidence of
severe hepatotoxicity among the individual PIs and NNRTIs
as well as a class comparison (i.e., PIs versus NNRTIs).
For both of the secondary objectives, the incidence was
expressed as the number of severe hepatotoxic events per
total months of exposure. To allow for comparison between
individual drugs and class comparisons, the incidence of
severe hepatotoxicity was normalized to 100 months of
exposure.
Data was entered into a Microsoft Access database
(Oﬃce 2003, Microsoft Corporation Seattle, WA, USA) and
analyzed using SAS (version 9.2, SAS Corporation, Cary,
Table 1: Baseline Demographics (N = 56).
Mean age (range) 50 years (30−62)
Sex
Male 42 (75%)
Female 14 (25%)
Race
African-American 43 (77%)
Caucasian 7 (13%)
Unknown 4( 6 % )
Hispanic 1( 2 % )
Hawaiian 1( 2 % )
HCV genotype
1 31 (55%)
2 2( 4 % )
Unknown 23 (41%)
Median baseline CD4 count (range) 233 cells/mm3 (5−960)
Median baseline viral load (range) 42,078 copies/mL
(<100−799,059)
Median baseline AST (range) 66 U/L (17−305)
Median baseline ALT (range) 56 U/L (10−259)
North Carolina). Descriptive statistics were used to analyze
the demographics, HCV genotype, CD4 count, viral load,
and incidence of severe hepatotoxicity.
3. Results
A total of 544 HIV/HCV coinfected patients were identiﬁed,
however, only 56 patients met all of the inclusion criteria.
The primary reason patients were excluded from the study
was that they were not treatment na¨ ıve at their ﬁrst clinic
visit (67.4%). Other reasons patients were excluded from the
study included: active or chronic hepatitis B virus (21.5%),
not receiving a PI- or NNRTI-based regimen (4.7%),
insuﬃcient data available, or not receiving antiretroviral
therapy during the study period. Baseline demographics
of the study population are described in Table 1. Patients
were mostly male (75%) with a mean age of 50 years
(±SD 7). A majority of patients were African-American
(77%) with a baseline median CD4 count and viral load
of 233cells/mm3 (range: 5−960 cells/mm3) and 42,078
copies/mL (range: <100−799,059 copies/mL), respectively.
There was insuﬃcient information available to quantify
baseline and subsequent alcohol consumption as well as
receipt of HCV therapy.
The overall cumulative exposure of NNRTIs or PIs
amongstudypatientswas1203and996months,respectively.
The greatest exposure within the NNRTI class and PI class
was with efavirenz (923 months) and lopinavir/ritonavir
(269 months), respectively. Atazanavir/ritonavir was the
PI with the second highest period of exposure of 213
months. For the primary endpoint, the incidence of severe
hepatotoxicity (grades 3 or 4) associated with any PI-
or NNRTI-based regimen was 10.7% (N = 6). SevereAIDS Research and Treatment 3
Table 2: Primary and secondary endpoints.
Primary endpoint:
Incidence of severe hepatotoxicity 10.7% (6/56 Patients)
Secondary endpoints
NNRTIs 3 cases/1203 months
0.249 cases per 100 months
of exposure
Efavirenz 2 cases/923 months
0.217 cases per 100 months
of exposure
Nevirapine 1 case/280 months
0.357 cases per 100 months
of exposure
PIs 3 cases/996 months
0.301 cases per 100 months
of exposure
Indinavir 1 case/97 months
1.03 cases per 100 months
of exposure
Nelﬁnavir 1 case/169 months
0.592 cases per 100 months
of exposure
Saquinavir/Ritonavir 1 case/100 months
1.00 cases per 100 months
of exposure
hepatotoxicity occurred with the following antiretrovirals:
efavirenz (N = 2), nevirapine (N = 1), indinavir (N = 1),
nelﬁnavir (N = 1), and saquinavir/ritonavir (N = 1)
(Table 2). All of the hepatotoxic events were grade 3, except
one grade 4 event with nevirapine. For secondary endpoints,
the normalized incidence of severe hepatotoxicity was the
highest with indinavir (1.03 cases/100 months of exposure)
(Table 2). Notably, no cases of severe hepatotoxicity were
observed with lopinavir/ritonavir or atazanavir/ritonavir,
which had the greatest months of exposure among PIs. The
normalized incidence of severe hepatotoxicity for NNRTIs
was 0.249 cases/100 months of exposure and 0.301 cases/100
months of exposure for PIs. All cases of hepatotoxicity
occurred in separate individuals. Five out of the 6 cases
of hepatotoxicity occurred on the ﬁrst regimen the patient
was prescribed. The time between starting antiretroviral
therapy and the development of hepatotoxicity ranged from
3 weeks to 18 months. Four of the 6 patients changed
regimens and subsequently had normalization of their
enzymes. Two patients remained on the same regimen
until the end of the study without normalization of their
enzymes.
Rationale for changing or discontinuing an NNRTI-
or PI-based regimen was identiﬁed in 33 cases. The most
commonreasonforchangingaregimenwasanadverseeﬀect
related to the medication (40%), resistance/treatment failure
(21%), nonadherence (18%), regimen simpliﬁcation (15%),
and hepatotoxicity (6%).
4. Discussion
HIV patients coinfected with HCV represent about a third of
theHIVpopulationintheUSandareatagreaterriskforliver
toxicitywiththeuseofpotentiallyhepatotoxicantiretrovirals
[6]. Questions regarding the safest antiretrovirals to use in
thispatientpopulationhavebeeninvestigatedinseveralpub-
lished clinical trials; however, many of these studies included
patients who were also infected with HBV. For example, in
a prospective cohort study of HIV patients coinfected with
either HBV or HCV (N = 298), hepatotoxicity was assessed
in patients who initiated either a PI-based (n = 211) or dual
nucleoside analog (n = 87) antiretroviral regimen [4]. Forty-
eight percent of patients in the study on a PI-based regimen
were coinfected with HCV, and were followed for a median
of approximately 6 months. Less than 3% of patients in the
study were coinfected with HBV. Overall, the incidence of
severe hepatotoxicity (grade 3 or 4 as deﬁned by the AIDS
Clinical Trials Group) in the entire study cohort (irregardless
of hepatitis coinfection) was 10.4%. Among HBV or HCV
coinfected patients, severe hepatotoxicity (grade 3 or 4)
occurred in 12%. Regimens that included ritonavir were
associated with a greater incidence of hepatotoxicity than
other regimens, but appeared to be unaﬀected by HCV/HBV
coinfection. In a multivariate model, use of ritonavir, but not
HBV/HCV coinfection status, was independently associated
with severe hepatotoxicity in the cohort (adjusted OR 8.6;
95% CI 3-24.6). Among those receiving nonritonavir based-
regimens, there was a higher incidence of hepatotoxicity
in those with HCV or HBV infection compared to those
without coinfection (9.4% versus 2.7% resp., RR 3.7 95%
CI 1.0−11.8) [4]. Lai et al. found that 33% of HIV/HCV
coinfected patients compared to 12% of noncoinfected
patients experienced severe hepatotoxicity on HAART [6].
Co-infected patients also developed liver enzyme elevations
more rapidly than noncoinfected patients (P = .0001). On
multivariate analysis, coinfection with HBV or HCV was
associated with severe hepatotoxicity (P = .001), but there
was no association with individual NRTI or PI medications
possibly due to small sample size [6]. A larger study
published in 2002 by Sulkowski et al. found a signiﬁcantly
greater risk of severe hepatotoxicity in coinfected patients
receiving nevirapine or efavirenz-based regimens compared
to HCV-uninfected persons [9]. In the HCV infected group,
19 of 124 (15.3%) patients on efavirenz based regimens
experienced severe hepatotoxicity compared to 6 of 188
(3.2%) uninfected HCV patients. A majority of patients in
the study received concurrent protease inhibitors and severe
hepatotoxicity was the highest among this group of patients;
however, the risk persisted irrespective of concomitant
protease inhibitor use [9].
Overall, our ﬁnding of an incidence of severe hepatotox-
icity in coinfected patients of 10.7% is similar to the rate
of severe hepatotoxicity related to HAART in noncoinfected
patients in these studies. In our study we found cases of
hepatotoxicity occurred with older, less commonly used
PIs (saquinavir, indinavir, and nelﬁnavir). Interestingly,
when reviewing newer agents such as lopinavir/ritonavir
and atazanavir/ritonavir which had the largest months of4 AIDS Research and Treatment
exposure for the PIs, no severe hepatotoxic events were
identiﬁed. This may suggest that these newer PIs may
be relatively safe to use in this patient population. The
commonly used NNRTI, efavirenz, was associated with two
cases of severe hepatotoxicity; however, this drug had the
most months of usage which led to a low normalized
incidence.
A major limitation of our study is the small sample size
since the patients were used as their own controls. Future
studies could include a control group of noncoinfected
patients so patients that are treatment experienced could
be included. Additionally, LFT changes documented in the
study could have been attributed to other causes such as
HCV or the use of other concomitant hepatotoxic drugs
or substances, such as alcohol. In a retrospective study
assessing severe hepatic injury after beginning HAART,
coinfected patients had a 3.99 greater chance of developing
severely elevated transaminase levels compared with patients
not coinfected with HCV. This risk was especially greater
in coinfected patients with identiﬁed alcohol abuse [8].
Although we attempted to include information regarding
alcohol intake, it was diﬃcult to assess this in a retrospective
study due to poor documentation in the medical records.
Informationregardingcurrentuseofinjectionorillicitdrugs
that could potentially contribute to the risk of hepatotoxicity
was not collected. Adherence to HAART was diﬃcult to
verify in patients followed at the DUMC Infectious Diseases
Clinic since it was not always documented in the patient’s
clinic notes nor did the facility dispense the medications
to their patients as is routinely done at the DVAMC. Risk
estimatescouldbehigherforthosewithbetteradherenceand
underestimated for those with poor adherence. Finally, due
to the low incidences, we had insuﬃcient power to compare
diﬀerent drugs or classes with one another.
In conclusion, additional studies are needed to gain a
better appreciation for the incidence of severe hepatotoxicity
inHIVpatientscoinfectedwithHCV.However,basedonthis
retrospective analysis, the incidence of severe hepatotoxicity
appears to be relatively low in HIV/HCV-coinfected patients
receiving either a PI- or NNRTI-based regimen.
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